| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2536667 | European Journal of Pharmacology | 2006 | 6 Pages |
Abstract
A chronically activated transgenic kallikrein kinin system with expression of human kallikrein-1 gene counteracts the progression of left ventricular contractile dysfunction after experimental myocardial infarction. Further studies have to show whether these results can be caused by other therapeutically options. Long acting bradykinin receptor agonists might be an alternative option to improve ischemic heart disease.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Matthias Koch, Frank Spillmann, Andreas Dendorfer, Dirk Westermann, Christine Altmann, Merdad Sahabi, Sophie Van Linthout, Michael Bader, Thomas Walther, Heinz-Peter Schultheiss, Carsten Tschöpe,